Date Announced: 12 Mar 2020
New CEO previously held senior executive roles at Second Sight and Spectranetics.
Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Will McGuire as Chief Executive Officer and a member of the company’s Board of Directors, effective March 30, 2020. Andrew Jackson, who has served as Interim CEO since August 2019, will remain Ra Medical’s Chief Financial Officer.
"Will’s extensive industry experience, particularly in the vascular space, makes him an ideal fit to lead Ra Medical," said Martin Colombatto, Chairman of Ra Medical Systems. "He’s built an impressive career at industry-leading medical device companies introducing new products, scaling commercial organizations, developing and implementing corporate strategies, exceeding sales projections and building high performing corporate cultures. His experience, energy and focus will help guide our product development, regulatory and commercial plans for DABRA, while we improve product reliability, expand our product offerings and enhance the experience for physicians and patients. We welcome Will to our executive team and to our board.
"On behalf of the Ra Medical Systems Board of Directors, I extend sincere thanks to Andrew Jackson for ably stepping into the CEO role over the past eight months," Mr. Colombatto added.
"I am excited for the opportunity to lead the talented team at Ra Medical. I believe the commercial opportunity for the Company is especially compelling given the advantages of DABRA photoablation for the treatment of peripheral artery disease," said Mr. McGuire. "DABRA quickly dissolves plaque with minimal vascular trauma in a disease that affects over 17 million people in the U.S. alone. I look forward to working with my new colleagues to advance the commercialization of DABRA and drive the adoption of this game-changing technology."
Mr. McGuire most recently served as President and CEO of Second Sight Medical Products (Nasdaq: EYES), a developer, manufacturer and marketer of implantable visual prosthetics to treat blindness. He will remain on the board of Second Sight as a Director. Previously he held leadership positions at Volcano Corporation including President of Americas Commercial and Senior Vice President and General Manager of Coronary Imaging, Systems and Program Management. Prior to that Mr. McGuire served as Vice President and General Manager of Patient Monitoring at Covidien, and President and Chief Executive Officer at AtheroMed, Inc., a venture capital-backed peripheral atherectomy company. For approximately five years, Mr. McGuire served as Chief Operating Officer for Spectranetics Corporation, a publicly-traded medical device company with laser-based atherectomy products for treating peripheral and coronary arterial disease. Earlier in his career, he held senior management positions at Guidant Corporation including General Manager of Latin America, Director of U.S. and Global Marketing for Vascular Intervention, and Production Manager for Coronary Stents. Mr. McGuire also held positions in Finance and Production at IVAC Medical Systems. Mr. McGuire received an engineering degree from the Georgia Institute of Technology, and his M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.
Source: Ra Medical Systems
E-mail: via web site
Web Site: www.ramed.com
|© 2023 SPIE Europe||